Visual Targeted Therapy of Hepatic Cancer Using Homing Peptide Modified Calcium Phosphate Nanoparticles Loading Doxorubicin Guided by T1 Weighted MRI

Nan-nan Zhang,Ri-sheng Yu,Min Xu,Xing-yao Cheng,Chun-miao Chen,Xiao-ling Xu,Chen-ying Lu,Kong-jun Lu,Min-jiang Chen,Meng-lu Zhu,Qiao-you Weng,Jun-guo Hui,Qian Zhang,Yong-Zhong Du,Jian-song Ji
DOI: https://doi.org/10.1016/j.nano.2018.06.014
2018-01-01
Abstract:Effective treatment and real-time monitoring of hepatic cancer are essential. A multifunctional calcium phosphate nanoparticles loading chemotherapeutic agent doxorubicin and magnetic resonance imaging contrast agent diethylenetriaminepentaacetic acid gadolinium (A54-CaP/Gd-DTPA/DOX) was developed for visual targeted therapy of hepatic cancer via T1-weighted MRI in real-time. A54-CaP/Gd-DTPA/DOX exhibited a higher longitudinal relaxivity (6.02 mM−1 s−1) than commercial MR contrast agent Gd-DTPA (3.3765 mM−1 s−1). The DOX release from the nanoparticles exhibited a pH dependent behavior. The cellular uptake results showed that the internalization of A54-CaP/Gd-DTPA/DOX into BEL-7402 cells was1.9-fold faster than that of HepG2 cells via A54 binding. In vivo experiments presented that A54-CaP/Gd-DTPA/DOX had higher distribution and longer retention time in tumor tissue than CaP/Gd-DTPA/DOX and free DOX, and also displayed great antitumor efficacy (95.38% tumor inhibition rate) and lower toxicity. Furthermore, the Gd-DTPA entrapped in the nanoparticles could provide T1-weighted MRI for real-time monitoring the progress of tumor treatment.
What problem does this paper attempt to address?